Recent studies have reported that lipids from neighboring adipose tissues, lipoproteins, lysophospholipids, and intracellular storage fat have the potential to maintain viability and growth of cancer cells 6,7,8,9
Adverse Reactions/Side Effects The following adverse reactions are also discussed elsewhere in the labeling: Lactic Acidosis [see Warnings and Precautions (5.1)] Pancreatitis [see Warnings and Precautions (5.2)] Heart Failure [see Warnings and Precautions (5.3)] Acute Renal Failure [see Warnings and Precautions (5.4)] Vitamin B12 Deficiency [see Warnings and Precautions (5.5)] Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues [see Warnings and Precautions (5.6)] Hypersensitivity Reactions [see Warnings and Precautions (5.7)] Severe and Disabling Arthralgia [see Warnings and Precautions (5.8)] Bullous Pemphigoid [see Warnings and Precautions (5.9)] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice
Drugs targeting weight management accounted for nearly half of the increase in drug spend in 2024, and the average list price for a GLP-1 is around $1,000 per month
Thankfully, semaglutide GLP-1 treatment has consistently been shown to provide positive results in the context of getting rid of belly fat
An FDA decision is expected in spring 2026
